Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.
Fiche publication
Date publication
août 2023
Journal
EJHaem
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AME Shanti
Tous les auteurs :
Amé S, Barraco F, Ianotto JC, Jourdan E, Rey J, Viallard JF, Wémeau M, Kiladjian JJ
Lien Pubmed
Résumé
Primary myelofibrosis (PMF) and polycythaemia vera (PV) are rare -negative myeloproliferative neoplasms, associated with an increased risk of thrombosis, haemorrhagic complications and progression to fibrosis or leukaemia or fibrosis for PV. Both diseases are characterised by biological and clinical heterogeneity, leading to great variability in their management in routine clinical practice. In this review, we present an updated overview of the diagnosis, prognosis and treatment of PMF and PV, and we discuss how our multidisciplinary expert group based across France translates this evidence-based knowledge into routine clinical practice.
Mots clés
diagnosis, myeloproliferative neoplasms, polycythaemia vera, primary myelofibrosis, prognosis, treatment
Référence
EJHaem. 2023 08;4(3):779-791